Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

Candice Hober; Lisa Fredeau; Anne Pham-Ledard; Marouane Boubaya; Florian Herms; Philippe Celerier; François Aubin; Nathalie Beneton; Monica Dinulescu; Arnaud Jannic; Nicolas Meyer; Anne-Bénédicte Duval-Modeste; Laure Cesaire; Ève-Marie Neidhardt; Élodie Archier; Brigitte Dréno; Candice Lesage; Clémence Berthin; Nora Kramkimel; Florent Grange; Julie de Quatrebarbes; Pierre-Emmanuel Stoebner; Nicolas Poulalhon; Jean-Philippe Arnault; Safia Abed; Bertille Bonniaud; Sophie Darras; Valentine Heidelberger; Suzanne Devaux; Marie Moncourier; Laurent Misery; Sandrine Mansard; Maxime Etienne; Florence Brunet-Possenti; Caroline Jacobzone; Romain Lesbazeilles; François Skowron; Julia Sanchez; Stéphanie Catala; Mahtab Samimi; Youssef Tazi; Dominique Spaeth; Caroline Gaudy-Marqueste; Olivier Collard; Raoul Triller; Marc Pracht; Marc Dumas; Lucie Peuvrel; Pierre Combe; Olivier Lauche; Pierre Guillet; Yves Reguerre; Ingrid Kupfer-Bessaguet; David Solub; Amélie Schoeffler; Christophe Bedane; Gaëlle Quéreux; Sophie Dalac; Laurent Mortier; Ève Maubec

doi:10.3390/cancers13143547

Back

Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

Journal article

Peer reviewed

Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group

Candice Hober, Lisa Fredeau, Anne Pham-Ledard, Marouane Boubaya, Florian Herms, Philippe Celerier, François Aubin, Nathalie Beneton, Monica Dinulescu, Arnaud Jannic, …

Cancers, Vol.13(14)

07/2021

DOI: https://doi.org/10.3390/cancers13143547

PMID: 34298764

Abstract

PD-1–blocking antibody

cemiplimab

chronic dermatosis

cutaneous squamous cell carcinoma

immunocompromised

real-life setting

skin cancer

Although cemiplimab has been approved for locally advanced (la) and metastatic (m) cutaneous squamous-cell carcinomas (CSCCs), its real-life value has not yet been demonstrated. An early-access program enrolled patients with la/mCSCCs to receive cemiplimab. Endpoints were best overall response rate (BOR), progression-free survival (PFS), overall survival (OS), duration of response (DOR) and safety. The 245 patients (mean age 77 years, 73% male, 49% prior systemic treatment, 24% immunocompromised, 27% Eastern Cooperative Oncology Group performance status (PS) ≥ 2) had laCSCCs (35%) or mCSCCs (65%). For the 240 recipients of ≥1 infusion(s), the BOR was 50.4% (complete, 21%; partial, 29%). With median follow-up at 12.6 months, median PFS was 7.9 months, and median OS and DOR were not reached. One-year OS was 73% versus 36%, respectively, for patients with PS < 2 versus ≥ 2. Multivariate analysis retained PS ≥ 2 as being associated during the first 6 months with PFS and OS. Head-and-neck location was associated with longer PFS. Immune status had no impact. Severe treatment-related adverse events occurred in 9% of the patients, including one death from toxic epidermal necrolysis. Cemiplimab real-life safety and efficacy support its use for la/mCSCCs. Patients with PS ≥ 2 benefited less from cemiplimab, but it might represent an option for immunocompromised patients.

Files and links (2)

url

Find in HALView

url

https://doi.org/10.3390/cancers13143547View

Published (Version of record) Open

Metrics

1 Record Views

See more details

Details

Title: Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: Real-life experience from the French CAREPI study group
Creators - without role: Candice Hober - Centre Hospitalier Universitaire de Lille
Lisa Fredeau - Hôpital Avicenne
Anne Pham-Ledard - Centre Hospitalier Universitaire de Bordeaux
Marouane Boubaya - Assistance Publique – Hôpitaux de Paris
Florian Herms - Hôpital Saint-Louis
Philippe Celerier - Centre Hospitalier de La Rochelle
François Aubin - Université Bourgogne Franche-Comté
Nathalie Beneton - Centre Hospitalier du Mans
Monica Dinulescu - Hôpital Pontchaillou
Arnaud Jannic - Hôpitaux Universitaires Henri-Mondor
Nicolas Meyer - Centre Hospitalier Universitaire de Toulouse
Anne-Bénédicte Duval-Modeste - Hôpital Charles-Nicolle
Laure Cesaire - Groupe d’Etude des Cétacés du Cotentin
Ève-Marie Neidhardt - Centre Léon Bérard
Élodie Archier - Hôpital Saint Joseph
Brigitte Dréno - Nantes Université
Candice Lesage - Centre Hospitalier Universitaire de Montpellier
Clémence Berthin - Centre Hospitalier Universitaire d'Angers
Nora Kramkimel - Assistance Publique – Hôpitaux de Paris
Florent Grange - Centre Hospitalier Universitaire de Reims
Julie de Quatrebarbes - Centre Hospitalier Annecy Genevois
Pierre-Emmanuel Stoebner - Institut des Biomolécules Max Mousseron
Nicolas Poulalhon - Hospices Civils de Lyon
Jean-Philippe Arnault - Centre Hospitalier Universitaire Amiens-Picardie
Safia Abed - Hôpital d'Instruction des Armées Sainte-Anne
Bertille Bonniaud - Centre Hospitalier Universitaire Dijon Bourgogne
Sophie Darras - Université d'été de Boulogne-sur-Mer
Valentine Heidelberger - Centre hospitalier Robert-Ballanger
Suzanne Devaux - Centre Hospitalier de la Côte Basque
Marie Moncourier - Centre Hospitalier Universitaire de Grenoble
Laurent Misery - Université de Bretagne Occidentale
Sandrine Mansard - Centre Hospitalier Universitaire de Clermont-Ferrand
Maxime Etienne - Centre Hospitalier de Cornouaille
Florence Brunet-Possenti - Hôpital Bichat-Claude-Bernard
Caroline Jacobzone - Hôpital Saint-Jacques
Romain Lesbazeilles - Centre Hospitalier Universitaire de Poitiers
François Skowron - Centre Hospitalier de Valence
Julia Sanchez - Université de Reims Champagne-Ardenne
Stéphanie Catala - Centre Hospitalier de Perpignan
Mahtab Samimi - Université de Tours
Youssef Tazi - Clinique Sainte Anne [Strasbourg]
Dominique Spaeth - Centre d'Oncologie de Gentilly
Caroline Gaudy-Marqueste - Aix-Marseille Université
Olivier Collard - Institute Cancer De La Loire Lucien Neuwirth
Raoul Triller - Institut Hospitalier Franco Britannique
Marc Pracht - Centre Hospitalier de Saint-Malo
Marc Dumas - CH René Dubos
Lucie Peuvrel - Institut de Cancérologie de l'Ouest
Pierre Combe - Pôle Universitaire Léonard de Vinci
Olivier Lauche - Clinique Clémentville
Pierre Guillet
Yves Reguerre - Centre Hospitalier Saint-Denis
Ingrid Kupfer-Bessaguet - Centre Hospitalier de Niort
David Solub - Hôpital Pasteur
Amélie Schoeffler - Centre Hospitalier Régional de Metz-Thionville
Christophe Bedane - Centre Hospitalier Universitaire de Limoges
Gaëlle Quéreux - Nantes Université
Sophie Dalac - Centre Hospitalier Universitaire Dijon Bourgogne
Laurent Mortier - Inserm
Ève Maubec - Hôpital Avicenne
Publication Details: Cancers, Vol.13(14)
Identifiers: 9963530809311
Academic Unit: Institut des Biomolécules Max Mousseron - IBMM
Language: English
Resource Type: Journal article
Local Fields: hal-03332168